Perflutren clinical trials
Also written Definity and Octafluoropropane.
How each study uses perflutren is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the perflutren studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Jul 2001 · DEFINITY · NDA 021064 (FDA, Drugs@FDA)
- European Union
- 17 May 1998 · Optison · EMEA/H/C/000166 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
62 studies that test it; most in 2020 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 5 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 54
Thomas Jefferson University (9) · Sunnybrook Health Sciences Centre (6) · UNC Lineberger Comprehensive Cancer Center (5) · Lantheus Medical Imaging (5) · Sidney Kimmel Cancer Center at Thomas Jefferson University (4) · Mayo Clinic (4) · Trust Bio-sonics, Inc. (3) · University of Southern California (3)
Often tested with
Tested in the same studies.
Sulfur Hexafluoride (4) · FS 069 (2) · Tissue Plasminogen Activator (1) · Irinotecan sucrosofate (1) · Irinotecan (1) · Fluorouracil (1) · Leucovorin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8, 3 in phase 3
Studies that test perflutren, phase 3 first.
- Feb 2027Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac EchocardiographyPhase 3 · Trust Bio-sonics, Inc.
- Jul 2027A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac EchocardiographyPhase 3 · Trust Bio-sonics, Inc.
- Aug 2027Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate CancerPhase 3 · Thomas Jefferson University
- Nov 2026Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast MassesPhase 1 · University of Southern California
- Mar 2027Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck CancerPhase 1 · Thomas Jefferson University
- Mar 2027Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal HypertensionNot applicable · Mayo Clinic
- May 2027Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant RadiotherapyEarly Phase 1 · Thomas Jefferson University
- Sep 2027Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord InjuryPhase 4 · University of Washington
Studies
Open first, then newest update. How each study uses perflutren is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 63
- Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate CancerNot yet recruitingPhase 3Thomas Jefferson UniversityNCT06024772Written as Perflutren lipid microsphere
- Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck CancerRecruitingPhase 1Thomas Jefferson UniversityNCT07501650Written as Definity
- A Study of Renal Microvessel Imaging for Chronic Kidney DiseaseEnrolling by invitationPhase 2Mayo ClinicNCT05764642Written as Definity
- Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal HypertensionRecruitingNot applicableMayo ClinicNCT06797193Written as Perflutren Lipid Microspheres
- A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac EchocardiographyNot yet recruitingPhase 3Trust Bio-sonics, Inc.NCT07740421Written as NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- Red Light Treatment in Peripheral Artery DiseaseRecruitingNot applicableUniversity of Alabama at BirminghamNCT03203239Written as Octafluoropropane
- Peripheral Blood Flow Responses to Electromagnetic EnergyRecruitingNot applicableUniversity of Alabama at BirminghamNCT02370199Written as octafluropropane
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant RadiotherapyRecruitingEarly Phase 1Thomas Jefferson UniversityNCT07436364Written as Definity
- Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast MassesRecruitingPhase 1University of Southern CaliforniaNCT06171607Written as Perflutren Lipid Microspheres
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic CancerNot yet recruitingPhase 1National Taiwan University HospitalNCT07314385Written as NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord InjuryRecruitingPhase 4University of WashingtonNCT06654804Written as Perflutren lipid
- MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast CancerRecruitingPhase 1Sunnybrook Health Sciences CentreNCT06633601Written as Definity Suspension for Injection
- Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast CancerRecruitingPhase 2Sunnybrook Health Sciences CentreNCT06185972Written as Definity
- MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin CancerRecruitingPhase 1Sunnybrook Health Sciences CentreNCT05620290Written as Definity
- Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck CancerRecruitingPhase 1Sunnybrook Health Sciences CentreNCT04431648Written as DEFINITY
- SHAPE Neoadjuvant Chemotherapy ResponseActive, not recruitingPhase 2/3Kibo NamNCT04715958Written as Perflutren Lipid Microspheres
- tSCI Contrast Enhanced Ultrasound StudyCompletedPhase 4University of WashingtonNCT04056988Written as Perflutren Lipid Microsphere
- Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac EchocardiographyActive, not recruitingPhase 3Trust Bio-sonics, Inc.NCT06815627Written as NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast CancerCompletedEarly Phase 1Thomas Jefferson UniversityNCT04721886Written as Perflutren Lipid Microcpheres
- A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac EchocardiographyCompletedPhase 1/2Trust Bio-sonics, Inc.NCT04185246Written as NH002 (Perflutren Lipid Microspheres) Injectable Suspension
See all 63 studies that test perflutren →
Given beside what is tested · 4 — perflutren is usual care or a partner of the new treatment
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary DiseaseRecruitingPhase 2The Hospital for Sick ChildrenNCT02740868Written as Xenon-129 and Perfluoropropane (19F)
- Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung DisordersTerminatedEarly Phase 1Thunder Bay Regional Health Research InstituteNCT02748798Written as PFP
- Neural Mechanism of Aldosterone-induced Insulin ResistanceWithdrawnPhase 4Wanpen VongpatanasinNCT02102243Written as DEFINITY® infusion
- Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 RadioembolizationWithdrawnNot applicableUniversity of Southern CaliforniaNCT03300401Written as Perflutren Lipid Microspheres
As the comparator · 1 — what is tested is compared with perflutren
Codes
What other systems call perflutren · ClinicalTrials.gg INT003166
- MeSH (NLM) C042852perflutrenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CK0N3WH0SRPERFLUTRENConfirmed FDA, NLM
- RxNorm 283753One source FDA
- NCI Thesaurus C47664PerflutrenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C042852 | perflutren | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CK0N3WH0SR | PERFLUTREN | Confirmed FDA, NLM |
| RxNorm | 283753 | — | One source FDA |
| NCI Thesaurus | C47664 | Perflutren | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.